The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Osteoporosis and Inflammation
Open accessAbstract
Osteoporosis represents a major healthcare burden, affecting approximately 10 million people aged over 50 years in the United States and with another 30 million or more at risk. One of the major contributing factors to osteoporosis is withdrawal of estrogen during menopause in women. Human and animal experiments have implicated pro-inflammatory cytokines as primary mediators of the accelerated bone loss at menopause including interleukin-1, tumor necrosis factor-alpha, and interleukin-6. Increased production of pro-inflammatory cytokines is associated with osteoclastic bone resorption in a number of disease states including rheumatoid arthritis, periodontitis, and multiple myeloma; estrogen withdrawal is associated with increased production of pro-inflammatory cytokines, and exposure of bone cultures to supernatants from activated leukocytes is associated with increased bone resorption. A major advance has been the discovery of RANKL, its receptor RANK, and the endogenous inhibitor osteoprotegerin. The binding of RANKL to RANK is essential for the differentiation and activation of osteoclasts and mediates the actions of essentially all known stimulators of osteoclastic bone resorption. RANKL expression is heightened in post- compared with pre-menopausal women, and this effect is attenuated by estrogen replacement therapy. RANKL is also a therapeutic target; a human antibody with high specificity and affinity to RANKL is currently under clinical evaluation for the treatment of osteoporosis in post-menopausal women and of metastatic bone disease in cancer patients with bone metastasis. Early data are promising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Role of osteoblasts in hormonal control of bone resorption—A hypothesis
Rodan, G. A., & Martin, T. J. (1981) · Calcified Tissue International · doi:10.1007/bf02409454 · Cited by 982
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes
Horton, J. E., Raisz, L. G., Simmons, H. A., Oppenheim, J. J., & Mergenhagen, S. E. (1972) · Science · doi:10.1126/science.177.4051.793 · Cited by 565
Research works printed but not linked: 43
- 2004, Bone Health and Osteoporosis: A Report of the Surgeon General
- Gass, 2006, Preventing osteoporosis-related fractures: an overview, Am J Med, 119, 3, 10.1016/j.amjmed.2005.12.017 · DOI · Paper page
- Anderson, 2004, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, JAMA, 291, 1701, 10.1001/jama.291.14.1701 · DOI · Paper page
- Curb, 2006, Venous thrombosis and conjugated equine estrogen in women without a uterus, Arch Intern Med, 166, 772, 10.1001/archinte.166.7.772 · DOI · Paper page
- Shumaker, 2004, Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, JAMA, 291, 2947, 10.1001/jama.291.24.2947 · DOI · Paper page
- Caputo, 1976, Failure of estrogens and androgens to inhibit bone resorption in tissue culture, Endocrinology, 98, 1065, 10.1210/endo-98-4-1065 · DOI
- Reddy, 1998, Control of osteoclast differentiation, Crit Rev Eukaryot Gene Expr, 8, 1, 10.1615/CritRevEukarGeneExpr.v8.i1.10 · DOI
- Boyce, 1989, Effects of interleukin-1 on bone turnover in normal mice, Endocrinology, 125, 1142, 10.1210/endo-125-3-1142 · DOI · Paper page
- Dewhirst, 1985, Purification and partial sequence of human osteo-clast-activating factor: identity with interleukin 1 beta, J Immunol, 135, 2562, 10.4049/jimmunol.135.4.2562 · DOI · Paper page
- Gowen, 1983, An interleukin 1 like factor stimulates bone resorption in vitro, Nature, 306, 378, 10.1038/306378a0 · DOI · Paper page
- Lorenzo, 1998, Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy, Endocrinology, 139, 3022, 10.1210/endo.139.6.6128 · DOI · Paper page
- Kimble, 1995, Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovari-ectomy period, Endocrinology, 136, 3054, 10.1210/endo.136.7.7789332 · DOI · Paper page
- Konig, 1988, Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary [3H]tetracy-cline excretion from prelabeled mice, J Bone Miner Res, 3, 621, 10.1002/jbmr.5650030607 · DOI
- Bertolini, 1986, Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors, Nature, 319, 516, 10.1038/319516a0 · DOI · Paper page
- Thomson, 1987, Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption, J Immunol, 138, 775, 10.4049/jimmunol.138.3.775 · DOI · Paper page
- Pluijm, 1991, Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix, Endocrinology, 129, 1596, 10.1210/endo-129-3-1596 · DOI
- Ishimi, 1990, IL-6 is produced by osteoblasts and induces bone resorption, J Immunol, 145, 3297, 10.4049/jimmunol.145.10.3297 · DOI · Paper page
- Jilka, 1992, Increased osteoclast development after estrogen loss: mediation by interleukin-6, Science, 257, 88, 10.1126/science.1621100 · DOI · Paper page
- Poli, 1994, Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion, Embo J, 13, 1189, 10.1002/j.1460-2075.1994.tb06368.x · DOI · Paper page
- Girasole, 1994, Interleukin-11: a new cytokine critical for osteoclast development, J Clin Invest, 93, 1516, 10.1172/JCI117130 · DOI · Paper page
- Hill, 1998, The cellular actions of interleukin-11 on bone resorption in vitro, Endocrinology, 139, 1564, 10.1210/endo.139.4.5946 · doi:10.1210/endo.139.4.5946
- Ogata, 1999, A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2, J Immunol, 162, 2754, 10.4049/jimmunol.162.5.2754 · DOI
- Kotake, 1999, IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, J Clin Invest, 103, 1345, 10.1172/JCI5703 · DOI · Paper page
- Goldring, 2002, Pathogenesis of bone erosions in rheumatoid arthritis, CurrOpin Rheumatol, 14, 406
- Bartold, 2005, Periodontitis and rheumatoid arthritis: a review, J Periodontol, 76, 2066, 10.1902/jop.2005.76.11-S.2066 · DOI · Paper page
- Anderson KC Shaughnessy JD , Jr. Barlogie B Ha-rousseau JL Roodman GD. Multiple myeloma. He-matology Am Soc Hematol Educ Program 2002 214 240 · DOI
- Mundy, 1974, Evidence for the secretion of an osteoclast stimulating factor in myeloma, N Engl J Med, 291, 1041, 10.1056/NEJM197411142912001 · DOI · Paper page
- Yeh, 2006, Treatment for myeloma bone disease, Clin Cancer Res, 12, 6279, 10.1158/1078-0432.CCR-06-0681 · DOI
- Pacifici, 1991, Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells, Proc Natl Acad Sci USA, 88, 5134, 10.1073/pnas.88.12.5134 · DOI · Paper page
- Ammann, 1997, Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency, J Clin Invest, 99, 1699, 10.1172/JCI119333 · DOI · Paper page
- Wong, 2005, Phenotypic differences in genetically identical organisms: the epigenetic perspective, Hum Mol Genet, 14, R11, 10.1093/hmg/ddi116 · DOI · Paper page
- Yasuda, 1998, Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc Natl Acad Sci USA, 95, 3597, 10.1073/pnas.95.7.3597 · DOI · Paper page
- Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X · DOI · Paper page
- Anderson, 1997, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, 390, 175, 10.1038/36593 · DOI · Paper page
- Fuller, 1998, TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts, J Exp Med, 188, 997, 10.1084/jem.188.5.997 · DOI · Paper page
- Roux, 2000, Bone loss. Factors that regulate osteoclast differentiation: an update, Arthritis Res, 2, 451, 10.1186/ar127 · DOI · Paper page
- Tanaka, 2005, Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system, Immunol Rev, 208, 30, 10.1111/j.0105-2896.2005.00327.x · DOI · Paper page
- Udagawa, 1990, Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells, Proc Natl Acad Sci USA, 87, 7260, 10.1073/pnas.87.18.7260 · DOI · Paper page
- Srivastava, 2001, Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation, J Biol Chem, 276, 8836, 10.1074/jbc.M010764200 · DOI · Paper page
- Nicklin, 2000, Arterial inflammation in mice lacking the inter-leukin 1 receptor antagonist gene, J Exp Med, 191, 303, 10.1084/jem.191.2.303 · DOI · Paper page
- Bucay, 1998, osteoprote-gerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev, 12, 1260, 10.1101/gad.12.9.1260 · DOI · Paper page
- Chen, 2006, Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context, Hum Mol Genet, 15, 519, 10.1093/hmg/ddi469 · DOI · Paper page
- Dougall, 2006, The RANK/RANKL/OPG triad in cancer-induced bone diseases, Cancer Metastasis Rev, 25, 541, 10.1007/s10555-006-9021-3 · DOI · Paper page
Cited by
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Depression as a disease of modernity: explanations for increasing prevalence
Hidaka, B. H. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.036 · Cited by 769
Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599
Kim, J. H., Yi, Y.-S., Kim, M.-Y., & Cho, J. Y. (2017) · Journal of Ginseng Research · doi:10.1016/j.jgr.2016.08.004 · Cited by 574
The multifaceted role of fibrinogen in tissue injury and inflammation
Luyendyk, J. P., Schoenecker, J. G., & Flick, M. J. (2019) · Blood · doi:10.1182/blood-2018-07-818211 · Cited by 555
Metadata
- Authors
- Mundy, G. R.
- Venue
- Nutrition Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-28
- Volume
- 65
- Issue
- 12 Pt 2
- Pages
- S147-S151
- ISSN
- 0029-6643 (ISSN-L)
- OpenAlex
- W1991762596
- Cited by
- 478
- References
- 11
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoporosis and Inflammation. https://app.cochat.ai/papers/10.1111/j.1753-4887.2007.tb00353.x
- The paper
- Mundy, G. R. (2008). Osteoporosis and Inflammation. Nutrition Reviews. https://doi.org/10.1111/j.1753-4887.2007.tb00353.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.